

Patients that used 3M™ Prevena™ Therapy experienced significant reduction in complications, reoperation and readmission rates for high-risk groin incision procedures.

Summary of Findings

Study¹ suggests that negative pressure therapy for patients at high risk for groin wound complications:

- Significantly reduces major wound complication
- Significantly reduces reoperation and readmission rates
- Closed incision negative pressure therapy (ciNPT) may lead to a reduction in hospital costs


ciNPT is recommended for all groin incisions considered at high risk for wound complications.

In addition to the above observed clinical outcomes, this study data² showed per-patient cost savings of \$6,045 for Prevena Therapy patients.

\$30,492 Prevena Therapy vs. \$36,537 Standard of Care (SOC).


Cost assessment includes variable hospital costs (for both the index hospitalization and all readmission days within 30 days related to any wound complication). Hospital variable costs (not charges) for each admission were obtained from hospital administration.

Results



Reduction in Surgical Site Complications*

11.9% (7/59) Prevena Therapy vs. 26.7% (16/60) SOC (p=0.001)*.




Reduction in Surgical Site Infections*

10.1% (6/59) Prevena Therapy vs. 31.6% (12/60) SOC (p=0.001)*.



Reduction in Return to OR*

8.5% (5/59) Prevena Therapy vs. 18.3% (11/60) SOC (p=0.05)*.



Reduction in Readmissions*

6.8% (4/59) Prevena Therapy vs. 16.7% (10/60) SOC (p=0.04)*.

Calculation(s) are derived based on relative patient group incidence rate reported in this study.

* Statistically significant (p<0.05)

Study Design

Prospective, single-centre, randomized controlled trial (Level I).

Study Purpose

This prospective RCT evaluated negative pressure therapy (3M™ Prevena™ Therapy) to decrease wound complications and associated healthcare costs.

Methods

- The study included 119 femoral incisions closed primarily after elective vascular surgery procedures.
- High-risk inclusion criteria: BMI > 30, pannus, re-operative surgery, prosthetic graft, poor nutrition, immunosuppression, or HbA1c>8
- 1:1 Randomized to standard gauze (n=60) vs. Prevena Therapy (n=59)
- Outcomes evaluated at post-operative day 30: wound complications, SSI, length of stay (LOS), reoperation, readmission

1. Kwon J, Staley C, McCullough M, et al. A Randomized Clinical Trial Evaluating Negative Pressure Therapy to Decrease Vascular Groin Incision Complications. *Journal of Vascular Surgery*. 2018; 68(6):1744-1752.

2. Cost Assessment includes variable hospital costs (for both the index hospitalization and all readmission days within 30 days related to any wound complication). Hospital variable costs (not charges) for each admission were obtained from hospital administration.

Understanding relevant risk factors for vascular procedures.

Patient Risk Stratification

Clinical data¹ suggests that patients should receive Prevena Therapy if they have **one or more** of the following risk factors:

- Re-operative surgery
- Prosthetic vascular graft
- Age > 50 years
- BMI > 30 kg/m²
- Significant pannus
- Malnutrition
- Smoker
- Immunosuppression
- Hypertension
- Coronary heart disease
- Chronic obstructive pulmonary disease (COPD)
- History or myocardial infarction
- Uncontrolled diabetes (hemoglobin A1c >8%)
- Chronic kidney disease
- Dyslipidaemia
- Hypercholesterolaemia
- Hyperhomocysteinaemia



Scan this QR code to learn more about when to use Prevena Therapy.

1. Kwon J, Staley C, McCullough M, et al. A Randomized Clinical Trial Evaluating Negative Pressure Therapy to Decrease Vascular Groin Incision Complications. *Journal of Vascular Surgery*. 2018;68(6):1744-1752.

It's time to update your dress code.



Available in Canada from your authorized 3M+KCI distributors.
KCI USA Inc., a 3M Company
KCI owned and operated by 3M Company

KCI Medical Canada Inc.
75 Courtneypark Dr., W.,
Unit 4
Mississauga, ON
L5W 0E3

KCI USA, Inc.
12930 IH 10 West
San Antonio, TX
78249

The 3M™ Prevena™ Incision Management System is intended to manage the environment of surgical incisions and surrounding intact skin in patients at risk for developing post-operative complications, such as infection, by maintaining a closed environment via the application of a negative pressure wound therapy system to the incision. The 3M™ Prevena™ Dressing skin interface layer with silver reduces microbial colonization in the fabric.

NOTE: Specific indications, limitations, contraindications, warnings, precautions, and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. This material is intended for healthcare professionals only.

3M, and Prevena are trademarks of 3M. Used under license in Canada. © 2022, 3M. All rights reserved. 2206-24203.

